Loading…
Navidea Biopharmaceuticals signed a definitive asset purchase agreement with Cardinal Health for its Lymphoseek product. Navidea will receive $80 million at closing plus up to $230 million in milestone payments through 2026, with over $20 million guaranteed over the next 3 years.